{
  "id": 15741531,
  "title": "UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease",
  "url": "https://urgent.news/2026/10/20/ueg-week-teva-and-sanofis-duvakitug-maintained-long-term-positive",
  "topic": "world",
  "section": "World",
  "published": "2026-10-20T12:26:24.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/ueg-week-teva-and-sanofis-duvakitug-maintained-long-term-positive-outcomes-in-new-phase-2b-data-for-ulcerative-colitis-and-crohns-disease"
  },
  "original_language": "en",
  "account": null,
  "summary": "Teva Pharmaceuticals and Sanofi have presented new positive data from the RELIEVE UCCD phase 2b long-term extension study in patients with moderate-to-severe ulcerative colitis or Crohn's disease. The study, identified as NCT05668013, showcased that duvakitug, an investigational human monoclonal antibody targeting TL1A protein, maintained clinically significant efficacy improvements across multiple endpoints over 44 weeks. Duvakitug works by potentially reducing inflammation and fibrosis in ulcerative colitis and Crohn's disease.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}